VISEN Pharmaceuticals (HKG:2561)

Hong Kong · Delayed Price · Currency is HKD

18.53

-0.28 (-1.49%)

Oct 9, 2026, 11:22 AM HKT

Market Cap	2.03B -56.0%
Revenue (ttm)	39.32M +3,950.1%
Net Income	-276.50M
EPS	-2.55
Shares Out	109.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,400
Open	18.51
Previous Close	18.81
Day's Range	18.51 - 18.90
52-Week Range	18.50 - 44.88
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parath... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2018

Employees 102

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2561

Full Company Profile

Financial Performance

In 2025, VISEN Pharmaceuticals's revenue was 136,000, a decrease of -95.10% compared to the previous year's 2.78 million. Losses were -253.42 million, 39.1% more than in 2024.

Financial numbers in CNY Financial Statements